BELLES Registry: Registry of the response and adverse effects of Belimumab in patients with Systemic Lupus Erythematosus
Main Article Content
Article Sidebar
https://orcid.org/0009-0003-2883-9465
Alicia Quiñonez
Astrid Paats
Yanira Yinde
Isabel Acosta Colmán
Abstract
Introduction: Belimumab has shown efficacy in systemic lupus erythematosus (SLE), although data from Latin American populations remain limited.
Objective: To evaluate therapeutic response and adverse events associated with Belimumab in Paraguayan patients with SLE.
Methods: Prospective longitudinal observational study including adult patients with SLE (2019 EULAR/ACR criteria) who initiated Belimumab between November 2023 and October 2024. Disease activity was assessed using SLEDAI-2K at weeks 0, 12, and 24.
Results: Seventeen patients were included, 88.2% female, with a mean age of 30.5 ± 8.2 years. Mean SLEDAI-2K decreased from 10.8 ± 5.4 at baseline to 6.8 ± 3.4 at week 12 and 6.9 ± 4.9 at week 24, with significant differences compared with baseline (p=0.027 and p=0.043, respectively). Reduction in anti-dsDNA positivity, complement consumption, and proteinuria was also observed. Mild infections were the most frequent adverse events. No unexpected severe adverse events were reported.
Conclusions: Belimumab showed significant reduction in SLE activity and an acceptable safety profile in this Paraguayan cohort.
How to Cite
Downloads
Article Details
Systemic lupus erythematosus, Belimumab, lupus nephritis
(2) Etchegaray-Morales I, Mendoza-Pinto C, Arellano-Avendaño FJ, Ibañez-Ovando S, Munguía-Realpozo P, Orbe-Sosa JG, et al. Epidemiology of systemic lupus erythematosus in Latin America. Reumatol Clin. 2024 Dec;20(10):560–6. Disponible en: https://doi.org/10.1016/j.reumae.2024.11.003
(3) Anders H-J, Saxena R, Zhao M-H, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Prim. 2020 Jan;6(1):7. Dsiponible en: https://doi.org/10.1038/s41572-019-0141-9
(4) Moriano C, Bellido-Pastrana D, San Román Gutiérrez C, Rodríguez E. Evolution of diagnosis and treatment for lupus nephritis in Spain. Nefrologia. 2023;43(6):668–75. Disponible en: https://doi.org/10.1016/j.nefroe.2023.12.006
(5) Estévez del Toro M, Varela Ceballos I, Chico Capote A, Kokuina E, Sánchez Bruzón Y, Casas Figueredo N. Factores predictores del desarrollo de nefritis lúpica después del diagnóstico de lupus eritematoso sistémico. Reumatol Clínica [Internet]. 2022;18(9):513–7. Disponible en: https://www.reumatologiaclinica.org/es-factores-predictores-del-desarrollo-nefritis-articulo-S1699258X21002308
(6) Díaz-Coronado JC, Rojas-Villarraga A, Hernandez-Parra D, Betancur-Vásquez L, Lacouture-Fierro J, Gonzalez-Hurtado D, et al. Clinical and sociodemographic factors associated with lupus nephritis in Colombian patients: A cross-sectional study. Reumatol Clin. 2021;17(6):351–6. Disponible en: https://doi.org/10.1016/j.reuma.2019.09.005
(7) Schwartzman-Morris J, Putterman C. Gender Differences in the Pathogenesis and Outcome of Lupus and of Lupus Nephritis. J Immunol Res [Internet]. 2012;2012(1):604892. Disponible en: https://doi.org/10.1155/2012/604892
(8) Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annu Rev Med. 2023;74:339–52. Disponible en: https://doi.org/10.1146/annurev-med-043021-032611
(9) Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int [Internet]. 2022 Feb 1;101(2):403–13. Disponible en: https://doi.org/10.1016/j.kint.2021.08.027
(10) LiverTox: Clinical and Research Information on DrugInduced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Belimumab. [Updated 2020 Dec 28]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31643176/
(11) Drugs.com. FDA Approves Benlysta to Treat Lupus [Internet]. 2011 Mar 9 [citado 2026 jun 1]. Disponible en: https://www.drugs.com/newdrugs/fda-approves-benlysta-lupus-2552
(12) European Medicines Agency. Benlysta (belimumab): EPAR – Medicine overview [Internet]. Amsterdam: EMA; 2011 [actualizado 2025 jul 30; citado 2026 jun 1]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta
How to Cite
Share
